AstraZeneca’s Alexion to expand into new biotech tower in New Haven

NEW HAVEN — The new biotech tower being built on College Street is still more than a year and a half away from completion, but one of Connecticut’s health sciences companies, Alexion Pharmaceuticals, has already committed to taking up space in the building.

Officials at Alexion, now part of global pharmaceutical giant AstraZeneca, did not specify how much space the company will occupy in the tower at 101 College St. Alexion’s research capabilities are expanding, doubling the space company lab floor in the city.

Alexion already has 500 employees as well as lab space at 100 College St., which is directly across from the construction site for the new biotech tower, said Carol, the company, which is developing drugs to treat patients. with rare diseases, is recruiting to fill 50 open positions. positions in New Haven.

More than half of those positions are in research and development, she said.

Once Alexion moved into the new space at 101 College, Carol said the company is planning new hires to expand its research and development capabilities in New Haven. But she declined to say how many more jobs could be added after the current hiring cycle.

Mike Piscitelli, New Haven’s economic development administrator, called Alexion’s announcement “exciting” and said it shows how the city’s real estate market is adapting to pandemic-related changes.

“With strong performance in growing economic sectors such as life sciences, as well as continued demand for housing, the real estate market is adjusting in part through conversions into medical/laboratory and innovation spaces as well than a conversion to residential use,” said Piscitelli. “We are all inspired by the science behind the growth of new jobs at Arvinas and Quantum-SI, which is relocating and expanding to Winchester Works as well as the conversion of several floors at 55 Church St. to support the new Elm City Bioscience Center .

Arvinas, another New Haven-based biotech, signed a 10-year lease to occupy approximately 160,000 square feet in the 525,000 square foot tower in early May 2021. Arvinas is based in the city’s science park complex.

Yale University announced in late May 2021 that it had signed a lease for 125,000 square feet of space over three floors in the Biotech Tower. The university is also providing financial support for a biotechnology incubator to be located on site.

Garrett Sheehan, president and CEO of the Greater New Haven Chamber of Commerce, said “the expansion demonstrates the growing potential that the bioscience industry, a critical component of Connecticut’s economy, sees in the New Haven area and its regional talent pool”.

“The expanded lab space at 101 College St. will be critical in addressing concerns about lab space in the state and we are excited about the work that will be conducted in the new space,” Sheehan said.

He said Alexion participates in the Student Program to Prepare Interns for Next Generation Talent, which is actively recruiting candidates for the summer 2022 paid internships. The program’s goal is to provide more than 100 opportunities this summer. in the life sciences industry to students at Connecticut colleges and universities, as well as students with Connecticut ties, according to Sheehan.

Alexion was founded in New Haven 30 years ago and after a stint in Cheshire, the company’s headquarters moved back to Elm City at the turn of the last decade.

But company officials announced in September 2017 that Alexion was moving its headquarters to Boston’s Seaport District. This move was completed in the summer of 2018.

AstraZeneca announced in December 2020 that it was acquiring Alexion in a $39 billion deal. This acquisition was finalized last July.

[email protected]é

About Terry Gongora

Check Also

India and the United States have common goals and challenges that bind them, says Minister Jitendra Singh

India and the United States have common goals and challenges that bind the two nations, …